Purpose of this Study
We are doing this study to find out if giving patients a drug called atezolizumab before and after surgery for recurrent glioblastoma can improve how their cancer responds.
Who Can Participate?
Eligibility
Adults ages 18+ who:<ul>
<li>Are diagnosed with glioblastoma (isocitrate dehydrogenase wildtype)</li>
<li>Have a recurrence after treatment with radiation and temozolomide</li>
<li>Plan to have surgery</li></ul>
For more information about who can join this study, please contact the study team at 919-684-5301.
<li>Are diagnosed with glioblastoma (isocitrate dehydrogenase wildtype)</li>
<li>Have a recurrence after treatment with radiation and temozolomide</li>
<li>Plan to have surgery</li></ul>
For more information about who can join this study, please contact the study team at 919-684-5301.
What is Involved?
If you join the study, you will:<ul>
<li>Have a physical exam and other tests</li>
<li>Have magnetic resonance imaging (MRI) scans of the brain</li>
<li>Have blood draws</li>
<li>Get atezolizumab before surgery</li>
<li>Get atezolizumab after surgery</li></ul>
<li>Have a physical exam and other tests</li>
<li>Have magnetic resonance imaging (MRI) scans of the brain</li>
<li>Have blood draws</li>
<li>Get atezolizumab before surgery</li>
<li>Get atezolizumab after surgery</li></ul>
Study Details
Full Title
A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
Principal Investigator
Mustafa
Khasraw
Protocol Number
PRO00113395
NCT ID
NCT06069726
Phase
N/A
Enrollment Status
Open to Enrollment